Related Experiment Video
Updated: Aug 5, 2026
Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
Published on: April 13, 2017
A strategy of microglia replacement alleviates microgliopathy in a CSF1R I794T hotspot mutation mouse model of
Xin Li1, Banglian Hu1, Chujun Wu2
1Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, Fujian Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, School of Medicine, Xiamen University, Xiamen, Fujian 361102, China.
Abstract:
The I794T hotspot mutation in the colony-stimulating factor 1 receptor (CSF1R) gene is associated with primary microgliopathy manifesting as leukoencephalopathy. In this study, we identify three Chinese probands harboring the CSF1R p.I794T variant and characterize their clinical and neuroimaging profiles. To elucidate disease mechanisms and explore therapeutic avenues, we generate a Csf1rI792T/+ knockin mouse model that carries this human mutation. These Csf1rI792T/+ mice exhibit hallmark features of CSF1R-related disorder (CSF1R-RD), including cognitive deficits, ventricular enlargement, reduced microglia, axonal spheroids, and demyelination. Transcriptomic analysis reveals that Csf1rI792T/+ microglia adopt an activated and disease-associated microglia (DAM)-like phenotype. Crucially, we develop and test a microglia replacement strategy, termed "duplicate-cyclic microglial depletion for transplantation" (DCMDT), which significantly ameliorates neuropathological deficits in Csf1rI792T/+ mice. Our findings highlight the pathological significance of the CSF1R p.I794T mutation and propose DCMDT as a promising therapeutic approach for neurodegenerative disorders driven by microglial dysfunction.
Insights
A specific mutation in the colony-stimulating factor 1 receptor (CSF1R) gene causes a rare brain disorder. A new mouse model and a novel microglia replacement therapy show promise for treating this condition.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- The colony-stimulating factor 1 receptor (CSF1R) gene harbors a hotspot mutation, I794T, linked to primary microgliopathy and leukoencephalopathy.
- Understanding the molecular mechanisms and developing therapeutic strategies for CSF1R-related disorders is crucial.
Purpose of the Study:
- To investigate the clinical and neuroimaging features of individuals with the CSF1R p.I794T variant.
- To establish and characterize a mouse model for CSF1R-related disorder (CSF1R-RD).
- To explore the efficacy of a novel microglia replacement therapy for CSF1R-RD.
Main Methods:
- Identified and characterized three Chinese probands with the CSF1R p.I794T variant.
- Generated a Csf1rI792T/+ knockin mouse model recapitulating key features of CSF1R-RD.
- Performed transcriptomic analysis on microglia from Csf1rI792T/+ mice.
- Developed and tested a microglia replacement strategy: "duplicate-cyclic microglial depletion for transplantation" (DCMDT).
Main Results:
- Csf1rI792T/+ mice displayed cognitive deficits, ventricular enlargement, reduced microglia, axonal spheroids, and demyelination.
- Transcriptomic analysis indicated Csf1rI792T/+ microglia exhibit an activated, disease-associated microglia (DAM)-like phenotype.
- The DCMDT strategy significantly ameliorated neuropathological deficits in the mouse model.
Conclusions:
- The CSF1R p.I794T mutation is pathologically significant in primary microgliopathy.
- The Csf1rI792T/+ mouse model effectively recapitulates CSF1R-RD.
- DCMDT presents a promising therapeutic avenue for neurodegenerative conditions involving microglial dysfunction.
More Related Videos
10:21Characterization and Isolation of Mouse Primary Microglia by Density Gradient Centrifugation
Published on: February 16, 2018
05:35Transplantation of Human Induced Pluripotent Stem Cell-Derived Microglia in Immunocompetent Mice Brain via Non-Invasive Transnasal Route
Published on: May 31, 2022
